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AbstrACt
Introduction Surveillance of unintended effects of 
pharmaceuticals (pharmacovigilance or drug safety) is crucial, 
as knowledge of rare or late side effects is limited at the time 
of the introduction of new medications into the market. Side 
effects of drugs may involve increased or decreased risk 
of cancer, but these typically appear after a long induction 
period. This fact, together with low incidences of many cancer 
types, limits the usefulness of traditional pharmacovigilance 
strategies, primarily based on spontaneous reporting of adverse 
events, to identify associations between drug use and cancer 
risk. Postmarketing observational pharmacoepidemiological 
studies are therefore crucial in the evaluation of drug-cancer 
associations.
Methods and analysis The main data sources in this project 
will be the Norwegian Prescription Database and the Cancer 
Registry of Norway. The underlying statistical model will be 
based on a multiple nested case–control design including all 
adult (~200 000) incident cancer cases within the age-range 
18–85 years from 2007 through 2015 in Norway as cases. 10 
cancer-free population controls will be individually matched 
to these cases with respect to birth year, sex and index date 
(date of cancer diagnosis). Drug exposure will be modelled 
as chronic user/non-user by counting prescriptions, and 
cumulative use by summarising all dispensions’ daily defined 
doses over time. Conditional logistic regression models adjusted 
for comorbidity (National Patient Register), socioeconomic 
parameters (Statistics Norway), concomitant drug use and, for 
female cancers, reproduction data (Medical Birth Registry), will 
be applied to identify drug-use–cancer-risk associations.
Ethics and dissemination The study is approved by the 
regional ethical committee and the Norwegian data protection 
authority. Results of the initial screening step and analysis 
pipeline will be described in a key paper. Subsequent papers 
will report the evaluation of identified signals in replication 
studies. Results will be published in peer-reviewed journals, at 
scientific conferences and through press releases.
IntroduCtIon  
rationale and evidence gaps
Surveillance of unintended effects of phar-
maceuticals (pharmacovigilance or drug 
safety) is an important task, as knowledge of 
rare or late side effects is limited at the time 
of the introduction of new medications into 
the market.1 Side effects of drugs may involve 
increased or decreased risk of cancer,2 3 but 
these typically appear after a long induction 
period.3 4 The excess risk of breast cancer 
induced by use of combined oestrogen–
progestin menopausal therapy becomes 
apparent only after 5–10 years of continued 
use,5 6 and chemoprevention of colorectal 
cancer with use of aspirin also requires 
many years of regular use.7 8 The suggested 
chemopreventive effects of statins, eg, against 
colorectal9 and prostate cancer,10 11 also derive 
from observations among long-term users of 
statins. The long latency of cancer develop-
ment together with low incidences of many 
cancer types limit the usefulness of tradi-
tional pharmacovigilance strategies, primarily 
based on spontaneous reporting of adverse 
events, to identify associations between drug 
use and cancer risk. Furthermore, carcino-
genic effects of drugs are not likely to be 
reported as adverse events, unless the drugs 
have a mechanism of action, which leads 
to suspicion. Postmarketing observational 
strengths and limitations of this study
 ► Large-scale study of drug-use–cancer-risk associa-
tions by linking and using information from multiple 
registries in Norway.
 ► The study design is a multiple nested case–control 
study comprising more than 2 000 000 individuals 
including all adult cancer cases diagnosed between 
2007 and 2015 in Norway and 10 matched controls.
 ► Adjustment for comorbidity, other drug use and so-
cioeconomic factors, but: not one size fits all—lack 
of data on confounders for certain drug-cancer 
combinations.
 ► Low power for some combinations of less frequent 
cancer types and drug groups.
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pharmacoepidemiological studies are therefore crucial in 
the evaluation of drug-cancer associations. Such studies 
have previously identified a range of important associa-
tions between drug use and cancer risk, eg, carcinogenic 
effects of immunosuppressants, menopausal hormone 
therapy and phenacetin.2 6 
Studies based on large administrative databases have 
contributed to the discovery of drugs with carcinogenic 
effects.2 6 The availability of these sources for systematic 
assessment of associations between long-term use of 
prescription drugs and cancer risk provides unique possi-
bilities for replication studies of the significant associa-
tions identified.
This study is based on high quality data from the 
Cancer Registry of Norway (CRN)12 and the Norwegian 
Prescription Database (NorPD) containing detailed indi-
vidual-level information on all dispensions of prescription 
drugs purchased by individual persons at all pharmacies in 
Norway since 2004.13 The availability of these Norwegian 
high quality nationwide registries of drug dispensations 
and cancer incidence provides an outstanding opportu-
nity to establish active surveillance of cancer risk associ-
ated with use of prescription drugs. A similar initiative has 
recently been established in Denmark14 and Sweden.15 
Within the Kaiser Permanente Program in California 
drug-cancer screening has been performed during the 
recent decades.16 These drug-cancer screening studies 
differ both with respect to the number of drugs and 
cancer types included in the study and the models and 
methods applied. As there is not enough experience and 
no consensus on how to best perform this type of studies, 
there is an urgent need to further explore the feasibility 
of different (combinations of) models and methods for 
this type of pharmacoepidemiological studies. In addition 
to the accumulation of evidence of drug-cancer screening 
signals, we aim to contribute to the method development 
for drug-cancer screening studies.
Aims and hypotheses
The primary aim of this study is the identification of asso-
ciations between prescription drugs and various types 
of cancer in a large-scale registry-based approach using 
existing Norwegian nationwide health and demographic 
registries. Thus, we propose a hypothesis-free screening 
approach to uncover drug-cancer associations that may, if 
validated and confirmed in other studies, indicate poten-
tial carcinogenic or chemopreventive effects of prescrip-
tion drugs. We also aim to gain methodological insights 
into the use of healthcare databases as well as pharma-
coepidemiological and statistical methods for the evalua-
tion of associations between drug use and cancer risk on 
a large scale.
The public health perspective of identifying associa-
tions between drugs and increased cancer risk is obvious, 
and potential dismissal of suspected associations and reas-
surance of the safety of drug intake with respect to cancer 
risk is of great public health importance. The latter can 
reassure patients about the safety of essential drugs and 
promote their appropriate use. Furthermore, identifica-
tion of potential chemopreventive effects of drugs also 
holds great value in the development of new targets for 
cancer prevention and treatment. This project will also 
establish knowledge with respect to study design, use of 
register data, multiple testing and statistical methodology 
within the field of pharmacoepidemiology, which is neces-
sary to establish regular periodic drug-cancer screening 
in the future.
MEthods And AnAlysIs
study population and data sources
The entire Norwegian population is covered by the 
publicly funded healthcare system. Several national 
administrative and disease registries have been estab-
lished that may be linked using a unique individual iden-
tification number assigned to all inhabitants of Norway. 
Thus, true population-based studies of disease may be 
efficiently conducted within the framework of the Norwe-
gian registry system.
The main data sources in the proposed project will 
be the NorPD and the CRN (figure 1). The NorPD will 
provide drug exposure data. This database covers all 
prescription drugs dispensed to persons in ambulatory 
care in Norway since 2004 with information on the date 
of dispensing, amount dispensed and the type of drug 
which is classified according to the Anatomical Ther-
apeutic Chemical (ATC) classification system.13 17 The 
CRN has recorded incident cases of cancer on a nation-
wide basis since 1953. The registry has been shown to have 
accurate and almost complete ascertainment of cancer 
cases.12 Furthermore, we will use data from the National 
Patient Registry (NPR), Statistics Norway (SSB) and the 
Medical Birth Registry of Norway (MBRN) to adjust for 
confounding factors, apply restrictions, and identify 
subgroups of special interest. Comorbidity indexes will 
be obtained from the NPR. Socioeconomic parameters 
(education and income) will be provided by SSB and 
reproduction data from MBRN.18 19
study design and statistical methods
The underlying study will be implemented as a multiple 
nested case–control design20 based on all adult (aged 18–85 
years) primary cancer cases (approximately 200 000) diag-
nosed from 2007 through 2015 in Norway as cases. Ten 
cancer-free controls will be individually matched (risk-set 
sampling) to each cancer case with respect to birth 
year, gender and index date (date of cancer diagnosis). 
Controls are thus cancer-free until index date, but might 
get cancer later in life. All cancer cases will be grouped 
topographically in ICD-10 categories (ICD-10: 10th revi-
sion of the international classification of diseases; as used 
in Cancer in Norway21) and histopathological subgroups. 
Information from the CRN on the cancer diagnosis (date 
of diagnosis, morphology, etc) will be provided as well. 
The cancer case and its matched controls are referred to 
as a matched case–control set.
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We chose a nested case–control design instead of the 
cohort design because the estimates from a conditional 
logistic regression of nested case–control data estimate 
the HR from the Cox regression using the entire cohort, 
furthermore with 10 controls per case the uncertainty of 
these estimates are only negligibly larger than the uncer-
tainty of the estimates using the entire cohort. At the 
same time, a nested case–control design is more compu-
tationally efficient, and from an ethical perspective using 
a dataset not larger than necessary to answer the research 
question is preferred.
For each ICD-10 category and corresponding histo-
pathological subgroups, associations between all second 
and fourth level drug classes of the ATC classification 
system and cancer risk will be evaluated. Each registered 
drug dispension contains information on the fifth level 
ATC drug class, date of dispension, type and amount 
defined daily dose (DDD) of the prescription. Thus, 
all feasible combinations of cancer and drug types are 
thus eligible for association testing (figure 2A). As a first 
step, we will focus on cancer types (and histopatholog-
ical subtypes) with good power (>70% to detect HR=1.5) 
across different types of drugs.
As a next step, we will retrospectively use information 
on the drug dispensions from index date back to 2004 for 
all individuals included in the study in order to quantify 
drug exposure. Figure 2B illustrates this for one fictive 
matched case–control set. For the drug type of interest, 
we start with information on dispensings of the drug 
type of interest from the index date back in time until 
2004 when NorPD started individual registration. We 
thus exclude data from the last year before index date, 
because drug exposure the last year before cancer diag-
nosis is unlikely to influence the cancer development 
and because drug intake in this period might be due to 
treatment of first cancer symptoms.3 22 We also exclude all 
individuals with dispensings of the drug type of interest in 
2004 in order to be able to determine the time point the 
individuals started with the drug intake. If a case needs 
to be removed based on this, the whole matched case–
control set will be excluded from the analysis. The anal-
ysis will be done both including and excluding individuals 
with dispensings of the drug type of interest in 2004, thus 
investigating the impact of long-term users on the results.
Based on this, we will define drug exposure in two 
different ways: the crude exposure defining chronic 
users and non-users based on the number of prescrip-
tions and the cumulative exposure based on the cumulative 
DDDs (figure 2C).
Crude exposure definition
Based on all dispensings within the time interval of 
interest (2005 to index date—1 year), drug use is grouped 
as non-users (0–1 drug dispensings), intermediate users 
(2–7 dispensings) and long-term users (at least 8 drug 
dispensings). We thus assume that eight prescriptions 
correspond to 2 years of drug use as drugs for chronic 
treatments are typically supplied for 3 months use at each 
dispensing.
Cumulative exposure definition
Based on all dispensings within the time interval of 
interest (2005 to index date—1 year), we will use the total 
number of defined daily doses (DDDs) across all dispens-
ings as exposure to model a cumulative effect and estab-
lish possible dose-response relationships.
Statistical methods
We will investigate (screen) the whole dataset across all 
drug–cancer-type combinations for associations between 
Figure 1 Data sources in the underlying study. ATC, Anatomical Therapeutic Chemical.
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drug use (exposure) and cancer (outcome). We will thus 
evaluate whether a drug is used disproportionally more 
often (or seldom) among cases compared with controls, 
which would indicate that the drug is associated with 
increased (or decreased) cancer risk. This approach does 
test for associations and does not imply approval or disap-
proval of causal effects. Moreover, this method is hypoth-
esis-free, but potentially hypothesis generating.
The statistical analyses of all drug–cancer-type combi-
nations will be performed based on matched-pair tech-
niques, that is, by applying conditional logistic regression 
with drug use modelled as described above. This 
approach will automatically adjust for age, gender and 
calendar time, as these variables are matching variables. 
In addition, we will adjust for comorbidity measured by 
the Charlson Comorbidity Index23 and the Norwegian 
Patient Registry Index.24 We will also adjust for concom-
itant use of other prescription drugs, if the drug intake 
exceeds 2 years, and education, income and occupation 
registered in SSB. Moreover, we will adjust for the region 
of residence. This model is similar to the one used by 
Pottegård et al.14
Interesting signals for a specific drug–cancer-type 
combination will be defined based on the resulting 
p values (see also below), which combine information 
from the effect and sample size, variation in the data 
and the assumed (and adjusted) type-I-error. Interesting 
signals will be evaluated further in post hoc tests both 
with respect to relevant anatomical and histopathological 
subtypes of the relevant cancer-type category of interest, 
as well as the fourth and fifth level drug classes of the ATC 
classification system for the drug classes of interest.
Multiple testing
As described above, we will initially test for all possible 
associations between drug use on the second and fourth 
level of the ATC classification system and the topolog-
ical and histological cancer type categories as described 
above. We assume the case–control studies to be indepen-
dent across cancer types, while tests within each cancer 
type across drug types are based on the same study popu-
lation and thus subject to multiple testing.
Obviously, in a hypothesis-generating approach like this, 
the chosen threshold should not be chosen too strict. On 
the other hand, resulting effect sizes or p values do not have 
an interpretation unless they will be compared with the 
underlying type-I-error by taking the amount and depen-
dency structure of statistical tests performed into account. 
Otherwise, the screening of large numbers of associations 
would produce statistically significant associations purely 
by chance. We need to find a balance between a long list of 
interesting findings, which includes too many false positives 
and a short list of interesting signals where too many true 
positive signals have been removed. The way we solve this 
is by choosing a liberal overall type-I-error threshold and a 
multiple testing adjustment of the resulting p values, which 
allows the investigators to interpret the signal strengths. 
Moreover, all interesting findings will be subject to further 
analyses and internal validation (see below). The hypotheses 
in our approach are dependent as they have a hierarchical 
Figure 2 Study design (A), included time period of drug dispensions (B) and exposure definition (C) in the underlying 
study. ATC, Anatomical Therapeutic Chemical; DDD, defined daily dose.
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structure. For example, the second, fourth and fifth level of 
the ATC classification system have a hierarchical structure 
since a specific fourth level ATC code consists of a number 
of non-overlapping fifth level ATC codes. This hierarchical 
structure of hypotheses can be most effectively taken into 
consideration by Closed Test Procedures. These proce-
dures are based on the closure principle25 and have become 
increasingly more popular as its application provides a foun-
dation for most multiple testing methods used in clinical 
and pharmacoepidemiological applications.26 27
Follow-up analysis and future perspectives
Interesting signals from the screening of drug-cancer asso-
ciations (as described above) do not only arise from true 
causal effects, and we will aim to filter out signals caused 
by biases like uncontrolled confounding or chance. In a 
subsequent internal validation step, we will filter the inter-
esting signals to separate out those signals, which qualify 
for further investigation. In order to achieve this, we will 
combine biological, pharmacological and epidemiological 
knowledge with several approaches as explained by Potte-
gård et al.28 Thus, robustness against the choice of study 
design, the assessment of dose-response patterns and the 
distribution of the cancer risk over time as well as consider-
ations of biological plausibility and possible uncontrolled 
confounding will be evaluated. For drug types usually given 
simultaneously with other drug types, similarities and inter-
actions will be evaluated.
Signals which persist after the internal validation step 
are subject to external validation. We have an established 
collaboration with the Danish Cancer Society and the 
University of Southern Denmark, which has already a 
similar ongoing project based on the Danish Cancer 
Registry and the Danish Prescription Registry.14 Their 
results and the results generated from the drug-cancer 
screening within the Kaiser Permanente Program in Cali-
fornia and the Swedish study15 16 will give us the possibility 
for replication. Thus, these data sources could be used to 
confirm any signals generated in the Norwegian setting 
together with a meta-analysis combining our results with 
those available from publications at that time-point.
Screening studies such as ours have the power to detect 
new drug–cancer-risk associations and will thus be hypoth-
esis-generating, that is, examine possible effects of drug 
intake on subsequent cancer development. Causal rela-
tionships between drug use and cancer disease cannot 
be established by association studies alone, but inter-
esting signals persisting after internal and external vali-
dation steps can be investigated in specifically designed 
follow-up studies where additional relevant confounders 
can be taken into consideration. Finally, when feasible, 
promising findings may be tested in animal or human in 
vitro studies, if suitable models are available.3
Power and sample size
The proposed screening study will include ~200 000 cancer 
cases and ~2 000 000 controls.
The power to calculate an association between drug use 
and cancer risk is dependent on the number of cancer 
cases (and controls) for a specific cancer type, the propor-
tion of cases and controls using a specific drug and the 
effect size for this particular combination of drug use and 
cancer type. We will test for association of many different 
combinations of cancer types and drugs with each having 
different parameters for power calculations. We will give 
an impression of the expected power in this project by 
calculating the power for different combinations of the 
underlying parameters described above. For reasons 
of caution and simplicity, we assume a multiple testing 
adjusted type-I-error threshold of 0.2/10 000=2.10−5 in 
the underlying power simulation. The adjusted type-I-
error threshold is reflecting the number of tests for all 
performed combinations of the second to fourth ATC 
levels and topological and histopathological cancer 
types. Since we will use a more sophisticated (and less 
stringent) multiple testing adjustment in the proposed 
study, our power estimates reflect a lower bound of the 
expected power. What we find is that the power is rela-
tively low (<80%) for less frequent cancer types and small 
effect sizes (OR=1.2). Increasing the OR to 1.5 expands 
the number of cancer sites with sufficient power but the 
vast majority still has a power below 80%. The power is 
sufficient (≥80%) for the more frequent cancer types and 
both effect sizes investigated here (OR=1.2, OR=1.5). 
Breast cancer serves as an example for the more frequent 
cancer types and liver cancer as an example for the less 
frequent cancer types.
All adult individuals in Norway aged 18–85 years at 
cancer diagnosis will be included in the study. Thus, the 
power will be as high as feasible in a nested case–control 
design with 1:10 matching based on Norwegian data at 
the present date and will rapidly increase in the future as 
there will be more cancer cases and prescriptions avail-
able for the analysis.
study strengths and limitations
As mentioned above, all individuals in Norway aged 18–85 
years at cancer diagnosis will be included in the study 
together with 10 matched controls for each case, leading 
to a large study sample of more than 2 million individuals. 
The unique Norwegian personal identification number 
can be used to link data from several nationwide registries 
in order to assess information on drug use, cancer inci-
dence, comorbidities and socioeconomic parameters for 
each individual included in this study.
Although taking age, sex, the date of cancer diagnosis 
(index date), comorbidities, concomitant drug use and 
socioeconomic parameters into consideration when 
evaluating possible drug-cancer associations, there are 
many possibilities for unknown confounders influencing 
these associations. Confounders can potentially generate 
spurious associations or mask real associations. The most 
obvious confounded associations (eg, drugs used for 
chronic obstructive pulmonary disease and lung cancer 
risk) will be excluded manually after the initial screening.
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Reverse causation denotes the phenomenon that an 
association between drug intake and cancer risk does 
not imply that the drug intake causes cancer.29 It could 
also be that a drug is given to treat an early manifesta-
tion of an outcome, which is not yet diagnosed. There are 
numerous examples of reverse causation within cancer 
epidemiology, and not only for drugs which should be 
kept in mind in evaluation of confounding.22 We will 
address reverse causation by routinely disregarding all 
information on drug use during the last year before the 
cancer diagnosis. This is also well justified for biological 
reasons,3 since such recent exposure is unlikely to have 
contributed to the carcinogenesis.
For those drug-use–cancer combinations where surveil-
lance of drugs users is more intense than for non-users, 
ascertainment bias plays a role, if the type of surveillance 
might lead to an (earlier) cancer diagnosis. This type of 
bias will partly be addressed by the adjustment for addi-
tional drug use and comorbidity. It will also be addressed 
in the internal validation step by excluding obvious pairs 
of drug-use–cancer-type combinations manually after the 
initially screening.
Patient and public involvement
As the study proposed by the present protocol is regis-
ter-based, the research question and outcome measures 
were not influenced by any specific patient priorities, 
experiences or preferences. Rather, their formulation 
was based upon our own priorities for patient benefit 
and result interpretation. The nested case–control study 
described by the protocol uses only data from nationwide 
population-based registers and thus will not include a 
recruitment process for patients, who will not be involved 
in neither the design nor conduct of the study. All results 
will be distributed via the relevant patient and drug user 
groups, as well as peer-reviewed journals and scientific 
conferences. The study described by the present protocol 
is not a randomised control trial and will not have 
measures of intervention that could burden patients in 
any way assessable.
Author affiliations
1Department of Research, Cancer Registry of Norway, Oslo, Norway
2Norwegian National Advisory Unit on Women’s Health, Women’s Clinic, Oslo 
University Hospital, Oslo, Norway
3Cancer Registry of Norway, Oslo, Norway
4Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 
Stockholm, Sweden
5Genetic Epidemiology Group, Folkhälsan Research Centerand Faculty of Medicine, 
Helsinki University, Helsinki, Finland
6Department of Community Medicine, University of Tromsø, The Arctic University of 
Norway, Tromsø, Norway
7Department of Pharmacology, Institute of Clinical Medicine, University of Oslo, Oslo, 
Norway
8Section for Pharmacology and PharmaceuticalBiosciences, Department of 
Pharmacy, University of Oslo, Oslo, Norway
9Regional Medicines Information and Pharmacovigilance Centre (RELIS), 
Department of Pharmacology, Oslo University Hospital, Oslo, Norway
10Department of Chronic Diseases and Aging, Nasjonalt folkehelseinstitutt, Oslo, 
Norway
11Clinical Pharmacology and Pharmacy, Department ofPublic Health, University of 
Southern Denmark, Odense, Denmark
12Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, 
Denmark
Contributors BKA prepared the study and the first version of the manuscript. NCS, 
JIM, GU, EW, HT, KBD, ØK, AP and SF contributed to the study design and reviewed 
and revised the protocol critically for important intellectual content, and approved 
the final versions. BKA is the guarantor.
Funding This project is funded by the Cancer Registry of Norway fund for research 
on cancer. 
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The study was approved by the regional ethical committee 
(2016/352 Identifikasjon av karsinogene og kjemopreventive effekter av 
reseptpliktige legemidler) and the Norwegian data protection authority. We also 
received permission from all involved registries, except for Statistics Norway which 
is pending. 
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology. 5th edn. 
Chichester, West Sussex, UK: Wiley- Blackwell, 2012.
 2. IARC. IARC Monographs on the evaluation of carcinogenic risks 
to humans. A review of human carcinogens. Volume 100 A: 
Pharmaceuticals. Lyon, 2012.
 3. Umar A, Dunn BK, Greenwald P. Future directions in cancer 
prevention. Nat Rev Cancer 2012;12:835–48.
 4. Burstein HJ, Schwartz RS. Molecular origins of cancer. N Engl J Med 
2008;358:527.
 5. Howell A, Evans GD. Hormone replacement therapy and breast 
cancer. Recent Results Cancer Res 2011;188:115–24.
 6. Friis S, Kesminiene A, Espina C, et al. European Code against 
Cancer 4th Edition: Medical exposures, including hormone therapy, 
and cancer. Cancer Epidemiol 2015;39(Suppl 1):S107–S119.
 7. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of 
colorectal neoplasia: an overview. Cancer Prev Res 2012;5:164–78.
 8. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise 
of precision chemoprevention. Nat Rev Cancer 2016;16:173–86.
 9. Lytras T, Nikolopoulos G, Bonovas S. Statins and the risk of 
colorectal cancer: an updated systematic review and meta-analysis 
of 40 studies. World J Gastroenterol 2014;20:1858–70.
 10. Bansal D, Undela K, D'Cruz S, et al. Statin use and risk of prostate 
cancer: a meta-analysis of observational studies. PLoS One 
2012;7:e46691.
 11. Tan P, Wei S, Tang Z, et al. LDL-lowering therapy and the risk of 
prostate cancer: a meta-analysis of 6 randomized controlled trials 
and 36 observational studies. Sci Rep 2016;6:24521.
 12. Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at 
the Cancer Registry of Norway: an overview of comparability, 
completeness, validity and timeliness. Eur J Cancer 
2009;45:1218–31.
 13. Furu K. Establishment of the nationwide Norwegian Prescription 
Database (NorPD)-new opportunities for research in 
pharmacoepidemiology in Norway. Norsk epidemiologi 2008;18.
 14. Pottegård A, Friis S, Christensen R, et al. Identification of 
Associations Between Prescribed Medications and Cancer: A 
Nationwide Screening Study. EBioMedicine 2016;7:73–9.
 15. Patel CJ, Ji J, Sundquist J, et al. Systematic assessment of 
pharmaceutical prescriptions in association with cancer risk: a 
method to conduct a population-wide medication-wide longitudinal 
study. Sci Rep 2016;6:31308.
 16. Friedman GD, Jiang SF, Udaltsova N, et al. Epidemiologic evaluation 
of pharmaceuticals with limited evidence of carcinogenicity. Int J 
Cancer 2009;125:2173–8.
 17. WHO. Guidelines for ATC classification and DDD assignment 2013. 
Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 
2012.
by copyright.












pen: first published as 10.1136/bm





7Andreassen BK, et al. BMJ Open 2019;9:e028504. doi:10.1136/bmjopen-2018-028504
Open access
 18. Irgens L. Tema-Forskningsmetoder-Medisinsk fodselsregister-et 
sentralt utgangspunkt for perinatalmedisinsk forskning. Tidsskrift for 
den Norske Laegeforening 2002;122:2546–8.
 19. Irgens LM. The Medical Birth Registry of Norway. Epidemiological 
research and surveillance throughout 30 years. Acta Obstet Gynecol 
Scand 2000;79:435–9.
 20. Shapiro S. Case-control surveillance. Strom BL, ed. 
Pharmacoepidemiology, 1994.
 21. Cancer Registry of Norway. Cancer in Norway 2016 - Cancer 
incidence, mortality, survival and prevalence in Norway. Oslo: Cancer 
Registry of Norway, 2017.
 22. Jørgensen TL, Hallas J, Friis S, et al. Comorbidity in elderly cancer 
patients in relation to overall and cancer-specific mortality. Br J 
Cancer 2012;106:1353–60.
 23. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying 
prognostic comorbidity in longitudinal studies: development and 
validation. J Chronic Dis 1987;40:373–83.
 24. Nilssen Y, Strand TE, Wiik R, et al. Utilizing national patient-register 
data to control for comorbidity in prognostic studies. Clin Epidemiol 
2014;6:395–404.
 25. Marcus R, Eric P, Gabriel KR. On closed testing procedures with 
special reference to ordered analysis of variance. Biometrika  
1976;63:655–60.
 26. Dmitrienko A, Wiens B, Westfall P. Fallback tests in dose-response 
clinical trials. J Biopharm Stat 2006;16:745–55.
 27. Henning KS, Westfall PH. Closed Testing in Pharmaceutical 
Research: Historical and Recent Developments. Stat Biopharm Res 
2015;7:126–47.
 28. Pottegård A, Hallas J, Wang SV, et al. Identifying signals of interest 
when screening for drug-outcome associations in health care data. 
Br J Clin Pharmacol 2018;84:1865–7.
 29. Pottegård A, Hallas J. New use of prescription drugs prior to a 
cancer diagnosis. Pharmacoepidemiol Drug Saf 2017;26:223–7.
by copyright.












pen: first published as 10.1136/bm
jopen-2018-028504 on 8 A
pril 2019. D
ow
nloaded from
 
